title: [Feasibility of HEV vaccine as control in HPV vaccine study and comparison of serological and risk factors between HEV and HPV infection among females].
abstract: OBJECTIVE
  Investigating the distribution of anti-hepatitis E virus (HEV-IgG), anti-human papillomavirus (HPV L1-IgG) and risk factors among female residents in Xinmi County, to explore the influencing factors of HPV vaccine study using HEV vaccinated population as a control.
  
  
  METHODS
  A screening study of cervical cancer in Xinmi County, Henan Province, was performed. The information of demographic characteristics and risk factors was collected using standard questionnaire. Nine ml blood was drawn from each woman for enzyme-linked immunosorbent assay to detect HEV-IgG and HPV L1-IgG antibody. Percentile, histogram and binary logistic regression model were used to describe the distribution of risk factors and their correlation to HPV and HEV infection.
  
  
  RESULTS
  The average age of the Xinmi female residents was 47.2 years, their positive rate of HPV L1 antibody was 26.8%, and that of HEV-IgG antibody was 31.0%, both of which were raised with age (P < 0.001). Single factor analysis showed that non-education, low-income and growing age were associated with HEV-IgG antibody positivity, and non-education, lowering ages of first sexual life and growing age were associated with HPV L1-IgG antibody positivity. Multivariable analysis showed that growing age, low-income and work as peasantry were independent risk factors for HEV-IgG antibody positivity, and lowering ages of first sexual life, non-education and growing age were independent risk factors for HPV L1-IgG antibody positivity.
  
  
  CONCLUSIONS
  Both the HEV-IgG and HPV L1-IgG antibodies positive rates increase with age. Age is the common risk factor of HEV-IgG and HPV L1-IgG antibodies in female residents in Xinmi County. The risk factors of HEV-IgG and HPV L1-IgG antibodies have no statistical association, neither cross reaction was found in the HEV-IgG and HPV L1-IgG detection.
authors.affiliation: Department of Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100021, China.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Cui
authors.forename: Jingchang
authors.initials: J
authors.lastname: Du
authors.forename: Mandong
authors.initials: M
authors.lastname: Fei
authors.forename: Wei
authors.initials: W
authors.lastname: He
authors.forename: Shaokai
authors.initials: S
authors.lastname: Zhang
authors.forename: Jia
authors.initials: J
authors.lastname: You
authors.forename: Yuzhi
authors.initials: Y
authors.lastname: Si
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Fan
authors.affiliation: Email: chenwen@cicams.ac.cn.
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
mesh_terms: D000906:Antibodies; D000914:Antibodies, Viral; D002681:China; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016751:Hepatitis E / Q000097:blood / Q000453:epidemiology*; D016752:Hepatitis E virus; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008875:Middle Aged; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000097:blood / Q000453:epidemiology*; D053918:Papillomavirus Vaccines; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis
chemical_list: D000906:Antibodies; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D053918:Papillomavirus Vaccines